Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$12.39 USD
-0.05 (-0.40%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $12.40 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RCUS 12.39 -0.05(-0.40%)
Will RCUS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RCUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCUS
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2
Pacira (PCRX) Tops Q2 Earnings Estimates
RCUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?
Other News for RCUS
RCUS's price falls by 0.4% on September 20, though its technical setup remains stable.
RCUS forms Stochastic Reached Overbought on September 19
Technical picture remains unchanged for RCUS after it rises 2.38% on September 18
The technical outlook for RCUS is unchanged after it rises 1.47% on September 16
RCUS's price rises by 0.52% on September 15, though its technical setup remains stable.